Pregabalin Capsule
Product Images NDC 71205-396

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-396). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-396-60 (Pregabalin Caps 150mg 90s Count)

Label for Pregabalin 150 mg capsules, prescription drug by Proficient Rx LP. The label indicates a package of 60 capsules with each capsule containing 150 mg of pregabalin. Capsules are described as white to off-white powder in size "2" hard gelatin capsules with a white opaque colored cap and body, imprinted with "SG" on the cap and "354" on the body in black ink. The product is manufactured by ScieGen Pharmaceuticals, Inc.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline for Pregabalin at doses of 200 mg, 100 mg, and 25 mg taken three times a day, along with a placebo group. The graph shows four lines representing the different dosage groups and placebo, with percent improvement in pain on the x-axis and percent of patients improved on the y-axis.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line chart comparing percent improvement in pain from baseline to percent of patients improved. The chart shows two lines representing Pregabalin 100 mg three times a day and placebo, illustrating response rates at different thresholds of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin dosages of 75 mg, 150 mg, and 300 mg taken twice a day to a placebo group, illustrating the response trends across different pain improvement percentages.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The x-axis shows percent improvement in pain from baseline (0 to 100), and the y-axis shows percent of patients improved (0 to 100). Three curves represent the different treatments' efficacy over the range of pain improvement.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting the percent of patients involved plotted against percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing trends of pain improvement percentages among these groups.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph depicting responder rates (%) in two studies (E1 and E3) comparing placebo and various dosages of pregabalin. The graph shows increasing responder rates with higher dosages, with statistical significance indicated versus placebo. Study E1 includes placebo, 50 mg/day, 150 mg/day, 300 mg/day, 600 mg/day. Study E3 includes placebo, 300 mg/day, and 600 mg/day dosages.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line chart showing seizure reduction as median percent change from baseline versus dose in mg/day. The graph displays data from four studies, indicated by different markers (circles, squares, triangles, and open triangles). Significant p-values are annotated for various doses, with seizure reduction increasing with dose.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line chart depicting percent improvement in pain from baseline (x-axis) against percent of patients improved (y-axis). Four lines represent different groups: Pregabalin 800 mg daily dose, 450 mg daily dose, 300 mg daily dose, and placebo, showing comparative effectiveness in pain improvement.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the percentage of subjects without LTR over 180 days for Pregabalin versus Placebo. The x-axis represents days, and the y-axis shows the estimated percentage of subjects without LTR. The Pregabalin group (solid line) maintains a higher percentage without LTR compared to the Placebo group (dashed line) across the observed period.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over baseline to Week 12 BOCF between Pregabalin and placebo. The x-axis represents percent improved from baseline, ranging from 0 to 100, and the y-axis shows the percent of subjects improved, from 0 to 100. Two lines display treatment effects: a solid line for Pregabalin and a dashed line for placebo, with the Pregabalin group showing higher improvement percentages overall.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved between Pregabalin and Placebo groups. The x-axis represents percent improvement from baseline to week 16 BOCF, ranging from 0 to 100, and the y-axis shows the percent of subjects improved, ranging from 0% to 100%. Two lines illustrate the data: a solid line for Pregabalin and a dashed line for Placebo, with the Pregabalin line consistently above the Placebo line.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula calculation for creatinine clearance (CLcr) based on age, weight, serum creatinine, and a factor for female patients. The formula is presented as a fraction with a multiplier for female patients. The image contains no specific product branding or labeling.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin showing its molecular arrangement with a carboxylic acid group (CO2H) and an amine group (NH2) attached to a branched carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.